Liaoning Chengda Biotechnology Co.,Ltd. (SHA:688739)

Market Cap	10.54B +4.3%
Revenue (ttm)	1.47B -14.5%
Net Income	177.94M -46.4%
EPS	0.43 -46.6%
Shares Out	411.25M
PE Ratio	59.48
Forward PE	26.70
Dividend	0.80 (3.12%)
Ex-Dividend Date	Jun 10, 2025

Volume	1,057,200
Average Volume	2,519,922
Open	25.93
Previous Close	25.90
Day's Range	25.90 - 26.04
52-Week Range	23.80 - 29.90
Beta	0.65
RSI	38.87
Earnings Date	Apr 21, 2026

About SHA:688739

Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company’s rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,788
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688739

Financial Performance

In 2024, SHA:688739's revenue was 1.68 billion, a decrease of -4.22% compared to the previous year's 1.75 billion. Earnings were 342.82 million, a decrease of -26.42%.